Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [carbonyl-^11C]GW842166
GW842166 · 3 trials · 3 indications
The index consisted of 24 questions (5 for pain, 2 for stiffness and 17 for physical and composite functions). The visual analog scale (VAS; 0-100 millimeter \[mm\]) was utilized in this study and participants were asked to rate joint pain they had in last 24 hours in the 5 pain items. Participants were asked to rate pain while performing following activities: walking on a flat surface, going up or down stairs; at night while in bed; sitting or lying and standing upright. Higher score (100) indicates extreme pain and lower score (0) indicates no pain. It was assessed on Day 1 pre-dose (Baseline), Day 1 (1 hour post-dose) and Day 14 (2-4 hours post-dose). Change from Baseline was planned to be calculated by subtracting Baseline value from post-Baseline value. Due to the early termination of this study, no formal statistical analysis was performed. Only summarized data is available.
| Arm | Type | Description |
|---|---|---|
| Overall study | EXPERIMENTAL | overall study population |
| Name | Type | Description |
|---|---|---|
| GW842166 | DRUG | 100 mg once daily |
| Placebo | DRUG | once daily |
Inclusion Criteria: * Male or female patients, 50 to 80 years of age. * A female is eligible to participate in this study if she is of: a) non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal (more than 1 year since last menst...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
GW842166 is an investigational small molecule developed by GSK plc for the treatment of pain associated with osteoarthritis, including osteoarthritis of the knee. It is a CB2 receptor agonist that has been studied in Phase 2 clinical trials. It is not approved for any indication.
GW842166 was studied for the treatment of pain in patients with osteoarthritis, including knee osteoarthritis. Clinical trials enrolled adults aged 40 and older with osteoarthritis pain, as well as patients with dental pain following third molar tooth extraction. The drug remains investigational and is not approved for any use.
GW842166 targets CNR2, also known as the cannabinoid CB2 receptor, where it acts as an agonist. This receptor is part of the endocannabinoid system and is a target of interest for pain conditions. The compound is a small molecule CB2 agonist.
GW842166 is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 2 clinical trials of the compound in osteoarthritis and dental pain.
GW842166 is in Phase 2 development. It is investigational and has not been approved by the FDA or any other regulatory agency. All three of its recorded Phase 2 trials are completed, and no trials are currently active.
GW842166 has been evaluated in three completed Phase 2 trials: NCT00479427 in osteoarthritis in the United Kingdom, NCT00447486 in knee osteoarthritis in Denmark, Germany, Spain and Sweden, and NCT00444769 in dental pain after third molar extraction in Germany, Italy and the United Kingdom.
Yes, [carbonyl-11C]GW842166 is an alternative name for GW842166. The carbon-11 label refers to a radiolabeled form of the compound used in research settings. Both names refer to the same CB2 receptor agonist developed by GSK.